BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

197 related articles for article (PubMed ID: 26937631)

  • 41. Tracing the origin of disseminated tumor cells in breast cancer using single-cell sequencing.
    Demeulemeester J; Kumar P; Møller EK; Nord S; Wedge DC; Peterson A; Mathiesen RR; Fjelldal R; Zamani Esteki M; Theunis K; Fernandez Gallardo E; Grundstad AJ; Borgen E; Baumbusch LO; Børresen-Dale AL; White KP; Kristensen VN; Van Loo P; Voet T; Naume B
    Genome Biol; 2016 Dec; 17(1):250. PubMed ID: 27931250
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Prognostic relevance of disseminated tumor cells in the bone marrow of patients with primary breast cancer--results of a standardized follow-up.
    Schindlbeck C; Pfab G; Jueckstock J; Andergassen U; Sommer H; Janni W; Friese K; Rack B
    Anticancer Res; 2011 Sep; 31(9):2749-55. PubMed ID: 21868516
    [TBL] [Abstract][Full Text] [Related]  

  • 43. HER2 status of bone marrow micrometastasis and their corresponding primary tumours in a pilot study of 27 cases: a possible tool for anti-HER2 therapy management?
    Vincent-Salomon A; Pierga JY; Couturier J; d'Enghien CD; Nos C; Sigal-Zafrani B; Lae M; Fréneaux P; Diéras V; Thiéry JP; Sastre-Garau X
    Br J Cancer; 2007 Feb; 96(4):654-9. PubMed ID: 17262082
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Relationship Between Hematogenous Tumor Cell Dissemination and Cellular Immunity in DCIS Patients.
    Gruber IV; Hartkopf AD; Hahn M; Taran FA; Staebler A; Wallwiener D; Brucker SY; Hanke J; Fehm T
    Anticancer Res; 2016 May; 36(5):2345-51. PubMed ID: 27127142
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Gene protein detection platform--a comparison of a new human epidermal growth factor receptor 2 assay with conventional immunohistochemistry and fluorescence in situ hybridization platforms.
    Stålhammar G; Farrajota P; Olsson A; Silva C; Hartman J; Elmberger G
    Ann Diagn Pathol; 2015 Aug; 19(4):203-10. PubMed ID: 25921313
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The presence and prognostic impact of apoptotic and nonapoptotic disseminated tumor cells in the bone marrow of primary breast cancer patients after neoadjuvant chemotherapy.
    Hartkopf AD; Taran FA; Wallwiener M; Hagenbeck C; Melcher C; Krawczyk N; Hahn M; Wallwiener D; Fehm T
    Breast Cancer Res; 2013; 15(5):R94. PubMed ID: 24099325
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Persistent tumor cells in bone marrow of non-metastatic breast cancer patients after primary surgery are associated with inferior outcome.
    Tjensvoll K; Oltedal S; Heikkilä R; Kvaløy JT; Gilje B; Reuben JM; Smaaland R; Nordgård O
    BMC Cancer; 2012 May; 12():190. PubMed ID: 22640166
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Disseminated tumour cells in the bone marrow in early breast cancer: morphological categories of immunocytochemically positive cells have different impact on clinical outcome.
    Synnestvedt M; Borgen E; Schlichting E; Schirmer CB; Renolen A; Giercksky KE; Nesland JM; Naume B
    Breast Cancer Res Treat; 2013 Apr; 138(2):485-97. PubMed ID: 23456230
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Correlation of circulating or disseminated tumor cells with the Oncotype DX Recurrence Score.
    Singh P; Tevis SE; Hall CS; Meas S; Hwang RF; Lucci A
    Breast Cancer Res Treat; 2020 Dec; 184(3):683-687. PubMed ID: 32888140
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Persistence of disseminated tumor cells in the bone marrow of breast cancer patients predicts increased risk for relapse--a European pooled analysis.
    Janni W; Vogl FD; Wiedswang G; Synnestvedt M; Fehm T; Jückstock J; Borgen E; Rack B; Braun S; Sommer H; Solomayer E; Pantel K; Nesland J; Friese K; Naume B
    Clin Cancer Res; 2011 May; 17(9):2967-76. PubMed ID: 21415211
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A perivascular niche in the bone marrow hosts quiescent and proliferating tumorigenic colorectal cancer cells.
    Möhrmann L; Zowada MK; Strakerjahn H; Siegl C; Kopp-Schneider A; Krunic D; Strunk D; Schneider M; Kriegsmann M; Kriegsmann K; Herbst F; Ball CR; Glimm H; Dieter SM
    Int J Cancer; 2020 Jul; 147(2):519-531. PubMed ID: 32077087
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Primary systemic therapy does not eradicate disseminated tumor cells in breast cancer patients.
    Becker S; Solomayer E; Becker-Pergola G; Wallwiener D; Fehm T
    Breast Cancer Res Treat; 2007 Dec; 106(2):239-43. PubMed ID: 17260094
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Disseminated tumor cells from the bone marrow of patients with nonmetastatic primary breast cancer are predictive of locoregional relapse.
    Hartkopf AD; Wallwiener M; Fehm TN; Hahn M; Walter CB; Gruber I; Brucker SY; Taran FA
    Ann Oncol; 2015 Jun; 26(6):1155-1160. PubMed ID: 25791636
    [TBL] [Abstract][Full Text] [Related]  

  • 55. [Detection of disseminated carcinoma cells in bone marrow and peripheral blood in primary breast cancer with RT/PCR of parathyroid hormone-related protein (PTHrP)].
    Liersch T; Gatzemeier W; Scharnberg P; Jürgens B; Wörmann B; Becker H; Rauschecker HF; Hiddemann W; Wulf GG
    Langenbecks Arch Chir Suppl Kongressbd; 1998; 115(Suppl I):277-80. PubMed ID: 14518259
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Quantitative determination of HER2 expression by confocal microscopy assay in CTCs of breast cancer.
    Cao S; Li Y; Li J; Li CF; Zhang W; Yang ZQ; Meng SD
    Oncol Rep; 2010 Feb; 23(2):423-8. PubMed ID: 20043103
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Evaluation of the clinical significance of HER2 amplification by chromogenic in situ hybridisation in patients with primary breast cancer.
    Dandachi N; Dietze O; Hauser-Kronberger C
    Anticancer Res; 2004; 24(4):2401-6. PubMed ID: 15330190
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Bone marrow versus sentinel lymph node involvement in breast cancer: a comparison of early hematogenous and early lymphatic tumor spread.
    Hartkopf AD; Banys M; Krawczyk N; Staebler A; Becker S; Hoffmann J; Hahn M; Wallwiener M; Fehm T
    Breast Cancer Res Treat; 2012 Jan; 131(2):501-8. PubMed ID: 21971730
    [TBL] [Abstract][Full Text] [Related]  

  • 59. ERalpha-status of disseminated tumour cells in bone marrow of primary breast cancer patients.
    Fehm T; Krawczyk N; Solomayer EF; Becker-Pergola G; Dürr-Störzer S; Neubauer H; Seeger H; Staebler A; Wallwiener D; Becker S
    Breast Cancer Res; 2008; 10(5):R76. PubMed ID: 18793387
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Simultaneous Detection of Disseminated and Circulating Tumor Cells in Primary Breast Cancer Patients.
    Hartkopf AD; Wallwiener M; Hahn M; Fehm TN; Brucker SY; Taran FA
    Cancer Res Treat; 2016 Jan; 48(1):115-24. PubMed ID: 25687853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.